Meta-analysis results: Is There a Link Between Obstetric Cholestasis and Gestational Diabetes?
BACKGROUND AND PURPOSE:
There is some evidence to suggest that GDM is more common following the onset of obstetric cholestasis
Mohan et al. (AJOG Global Reports, 2021) determined the prevalence of GDM in women with cholestasis of pregnancy
Systematic review and meta-analysis
Observational, cross-sectional/prevalence, case-control, and cohort studies
Studies that described epidemiological data of the pregnant population with cholestasis and GDM
Prevalence of GDM in the cholestasis population
Prevalence of GDM in the cholestasis population versus the non- cholestasis population
21 studies | 16,748 patients
Prevalence of GDM in the cholestasis population: 13.9%
GDM was more common in the cholestasis population compared to the non- cholestasis population
OR 2.129 (95% CI, 1.697 to 2.670); 10 studies
Severe cholestasis was twice as likely to be associated with GDM vs mild cholestasis
OR 2.168 (95% CI, 1.429 to 3.289); 4 studies
Women with cholestasis of pregnancy have a higher prevalence of GDM than the general population
The risk of GDM was twice as high with severe cholestasis compared to mild cholestasis
The authors acknowledge that while this is the largest meta-analysis to date on the topic, the studies are observational in design | Currently, there is no known mechanism for the relationship between cholestasis of pregnancy and GDM
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan